Closed System Transfer Devices (CSTDs) for Chemotherapy: More Than an Added Layer of Protection
While many facilities use some protective measures for chemo drugs, recent figures suggest that only 41% have adopted CSTDs.
While many facilities use some protective measures for chemo drugs, recent figures suggest that only 41% have adopted CSTDs.
Octreotide has demonstrated promising results vs. a subset of carcinoid tumors, despite a lower overall response rate.
The FDA has approved Akynzeo (netupitant and palonosetron; Eisai) to treat nausea and vomiting in patients undergoing chemotherapy.
New regimen resulted in significantly less chemotherapy-induced nausea and vomiting in multiple myeloma patients.
A particular protein in the bone marrow prompts stem cells to repair the human blood system after chemotherapy and radiation
Patients with advanced esophageal cancer who underwent radiation therapy alone experienced fewer swallowing complications.
NDA submitted for rolapitant for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Early studies show that continual low-dose chemotherapy lessens toxicity.
The anti-cancer effect of chloroquine when combined with conventional chemo has been well-documented.
Inflammatory breast cancer cells’ mechanism of chemotherapy resistance identified.